Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BIIB vs TECH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: BIIB 5 – 1 TECH Matrix Metrics: BIIB 4 – 6 TECH

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Bio-Techne Corp. (TECH) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas TECH carries 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin).

  • Composite vs. Pillar Nuance: While TECH currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 21.7% operating margin) and revenue trajectory (+10.6% vs. +4.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIIB vs TECH
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03
TECH NASDAQ
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.79
-0.01% 1D
Market Cap $11.4B
TTM Revenue $1.23B
Forward P/E 42.8x
Beta / 30D Vol 0.37β · 1% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.7 · SMA20: $72.71 · SMA50: $72.54

6-Pillar Scorecard Institutional Category Breakdown (BIIB 5 – 1 TECH)

Columns: Metric · BIIB · TECH
1. Valuation Multiples BIIB
Forward P/E 15.6x 42.8x
Trailing P/E 109.9x 66.8x
PEG Ratio 3.45x 2.18x
EV / Revenue 4.2x 9.3x
2. Growth & Scale BIIB
Revenue Growth (YoY) +10.6% +4.6%
Earnings Growth (YoY) -84.8% -25.0%
TTM Revenue (USD) $10.3B $1.23B
Market Cap $37.0B $11.4B
3. Profitability & Quality BIIB
Gross Margin 75.8% 66.2%
Operating Margin 23.5% 21.7%
Net Profit Margin 3.4% 14.0%
Return on Equity (ROE) 1.9% 8.3%
4. Balance Sheet & Cash Flow TECH
Cash Generation (TTM) $1.64B $325M EBITDA
Cash Flow Margin 16.0% 26.5% EBITDA Mgn
Net Cash / Leverage $6.50B Net Debt (0.41x D/E) $13.79 Book/Sh · 8.3% ROE
Dividend Yield None (0.00%) 0.33%
5. Options & Positioning BIIB
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 18.4% (6th %ile) 40.9% (6th %ile)
Put/Call OI Skew 0.77x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity 52.3% of Rev ($5.39B) 44.5% of Rev ($547M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIIB (4) vs TECH (6)
Institutional Metric BIIB TECH Criterion Row Edge
Market Capitalization
Scale
$37.0B $11.4B Larger Scale BIIB
Trailing P/E Ratio
Valuation
109.9x 66.8x Lower Multiple TECH
Forward P/E Ratio
Valuation
15.6x 42.8x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+10.6% +4.6% Higher Growth BIIB
Operating Margin (TTM)
Profitability
23.5% 21.7% Higher Margin BIIB
Net Profit Margin
Profitability
3.4% 14.0% Higher Margin TECH
Return on Equity (ROE)
Capital Efficiency
1.9% 8.3% Higher ROE TECH
52-Week Range Position
Momentum
92% ($160–$261) 100% ($43–$73) Stronger Trend TECH
Beta / 30D Volatility
Risk Regime
0.27β · 36% Vol 0.37β · 1% Vol Lower Realized Risk TECH
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 52.4 / 100 (HOLD) Higher Composite TECH
Trailing 12M Revenue (USD)
Operating Scale
$10.3B $1.23B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.8% 66.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.45x PEG · 4.2x EV/Rev 2.18x PEG · 9.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.64B ($6.50B Net Debt (0.41x D/E)) $325M EBITDA ($13.79 Book/Sh · 8.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +8.33 pp
BIIB: +8.63% · TECH: +0.3%
3M Horizon BIIB +18.11 pp
BIIB: +18.9% · TECH: +0.79%
6M Horizon TECH +32.14 pp
BIIB: +31.69% · TECH: +63.83%
1Y Horizon BIIB +33.59 pp
BIIB: +53.41% · TECH: +19.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIIB vs TECH. Trailing 12-month operating profitability (BIIB 23.5% vs TECH 21.7%) and valuation multiples (BIIB 15.6x vs TECH 42.8x Forward P/E) are benchmarked directly in Pillar 4 below.

BIIB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.3B
Gross Margin75.8%
Op. Margin23.5%
ROE / Fwd P/E1.9% · 15.6x
TECH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin66.2%
Op. Margin21.7%
ROE / Fwd P/E8.3% · 42.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TECH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published
TECH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment 44.5% of Rev ($547M)
90D Engineering Disclosures 0 Published

Investor FAQ BIIB vs TECH Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Bio-Techne Corp. (TECH) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BIIB carries a Unified Composite Score of 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin), whereas TECH carries 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin). Composite vs. Pillar Nuance: While TECH currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 21.7% operating margin) and revenue trajectory (+10.6% vs. +4.6% YoY).

BIIB leads the Growth & Scale pillar: BIIB posts +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin), compared with TECH at +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin). On trailing 12-month operating scale, BIIB generates $10.3B in USD-normalized revenue versus $1.23B for TECH. In operating R&D and SG&A reinvestment, BIIB deploys 52.3% of Rev ($5.39B) (0 90-day corporate R&D disclosures) versus 44.5% of Rev ($547M) (0 disclosures) for TECH.

BIIB screens cheaper on headline valuation multiples. BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin), whereas TECH trades at 42.8x Forward P/E, 66.8x Trailing P/E, 2.18x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIIB (1.9% ROE) versus TECH (8.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk). By comparison, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 1% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.